TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 213 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2022. The put-call ratio across all filers is 3.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $285,333,000 | +187.8% | 3,791,801 | +2.7% | 0.01% | +200.0% |
| Q1 2022 | $99,138,000 | -45.1% | 3,692,214 | -2.4% | 0.00% | -40.0% |
| Q4 2021 | $180,466,000 | -27.6% | 3,783,325 | +0.9% | 0.01% | -28.6% |
| Q3 2021 | $249,161,000 | -17.2% | 3,750,736 | -2.7% | 0.01% | -12.5% |
| Q2 2021 | $300,782,000 | +0.1% | 3,855,203 | +21.3% | 0.01% | -11.1% |
| Q1 2021 | $300,574,000 | -21.9% | 3,177,645 | +0.6% | 0.01% | -25.0% |
| Q4 2020 | $384,727,000 | +62.9% | 3,157,387 | +16.8% | 0.01% | +33.3% |
| Q3 2020 | $236,123,000 | +59.6% | 2,702,881 | +18.0% | 0.01% | +50.0% |
| Q2 2020 | $147,979,000 | +57.0% | 2,291,030 | +8.5% | 0.01% | +20.0% |
| Q1 2020 | $94,271,000 | -29.0% | 2,110,869 | -0.9% | 0.01% | 0.0% |
| Q4 2019 | $132,729,000 | +392.8% | 2,130,831 | +197.5% | 0.01% | +400.0% |
| Q3 2019 | $26,931,000 | +14.5% | 716,296 | +24.0% | 0.00% | 0.0% |
| Q2 2019 | $23,520,000 | – | 577,888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |